FI111257B - Menetelmä terapeuttisesti käyttökelpoisten 5-aryyli-indolijohdannaisten valmistamiseksi sekä uudet välituoteyhdisteet - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 5-aryyli-indolijohdannaisten valmistamiseksi sekä uudet välituoteyhdisteet Download PDF

Info

Publication number
FI111257B
FI111257B FI934825A FI934825A FI111257B FI 111257 B FI111257 B FI 111257B FI 934825 A FI934825 A FI 934825A FI 934825 A FI934825 A FI 934825A FI 111257 B FI111257 B FI 111257B
Authority
FI
Finland
Prior art keywords
ylmethyl
indol
formula
compound
reaction
Prior art date
Application number
FI934825A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI934825A0 (fi
FI934825L (fi
Inventor
John Eugene Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI934825A0 publication Critical patent/FI934825A0/fi
Publication of FI934825L publication Critical patent/FI934825L/fi
Application granted granted Critical
Publication of FI111257B publication Critical patent/FI111257B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
FI934825A 1992-11-02 1993-11-01 Menetelmä terapeuttisesti käyttökelpoisten 5-aryyli-indolijohdannaisten valmistamiseksi sekä uudet välituoteyhdisteet FI111257B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
US97075892 1992-11-02

Publications (3)

Publication Number Publication Date
FI934825A0 FI934825A0 (fi) 1993-11-01
FI934825L FI934825L (fi) 1994-05-03
FI111257B true FI111257B (fi) 2003-06-30

Family

ID=25517470

Family Applications (2)

Application Number Title Priority Date Filing Date
FI934825A FI111257B (fi) 1992-11-02 1993-11-01 Menetelmä terapeuttisesti käyttökelpoisten 5-aryyli-indolijohdannaisten valmistamiseksi sekä uudet välituoteyhdisteet
FI20002505A FI20002505L (fi) 1992-11-02 2000-11-15 5-aryyli-indolijohdannaisia

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20002505A FI20002505L (fi) 1992-11-02 2000-11-15 5-aryyli-indolijohdannaisia

Country Status (27)

Country Link
US (1) US5886008A (OSRAM)
EP (2) EP1094064A1 (OSRAM)
JP (1) JP2788551B2 (OSRAM)
KR (1) KR0163371B1 (OSRAM)
CN (1) CN1051313C (OSRAM)
AT (1) ATE202102T1 (OSRAM)
AU (1) AU685066B2 (OSRAM)
BR (1) BR9307348A (OSRAM)
CA (2) CA2340999C (OSRAM)
CZ (1) CZ283001B6 (OSRAM)
DE (1) DE69330351T2 (OSRAM)
DK (1) DK0666858T3 (OSRAM)
EG (1) EG20396A (OSRAM)
ES (1) ES2157224T3 (OSRAM)
FI (2) FI111257B (OSRAM)
GR (1) GR3036579T3 (OSRAM)
HU (1) HU222235B1 (OSRAM)
IL (1) IL107386A (OSRAM)
MY (1) MY109696A (OSRAM)
NO (1) NO309652B1 (OSRAM)
NZ (1) NZ257059A (OSRAM)
PL (1) PL176091B1 (OSRAM)
PT (1) PT666858E (OSRAM)
RU (1) RU2134266C1 (OSRAM)
TW (1) TW251284B (OSRAM)
WO (1) WO1994010171A1 (OSRAM)
ZA (1) ZA938137B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
BR9407402A (pt) * 1993-08-31 1996-11-05 Pfizer Derivados do 5-arilindol
WO1995021836A1 (en) * 1994-02-10 1995-08-17 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
EA001113B1 (ru) * 1995-03-20 2000-10-30 Эли Лилли Энд Компани 5-замещенные-3-(1,2,3,6-тетрагидропиридин-4-ил)- и 3-(пиперидин-4-ил)-1н-индолы и их фармацевтически приемлемые соли и сольваты, фармацевтическая композиция на их основе, способ активации рецепторов 5-нт1 и способ ингибирования нейронной белковой транссудации
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
SK179899A3 (en) * 1997-07-03 2001-12-03 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2004041162A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Inhibitors of akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
JP2006524254A (ja) 2003-04-24 2006-10-26 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害剤
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
BRPI0413740A (pt) * 2003-08-21 2006-10-24 Osi Pharm Inc composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
SG149828A1 (en) 2003-10-03 2009-02-27 3M Innovative Properties Co Alkoxy substituted imidazoquinolines
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
DE102004014304A1 (de) * 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
EP1844201B1 (en) 2005-02-04 2016-08-24 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
BRPI0709077A2 (pt) * 2006-03-22 2012-04-10 Janssen Pharmaceutica Nv derivados de alquilaminas cìclicas como inibidores da interação entre mdm2 e p53
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
HK1218623A1 (zh) 2013-03-15 2017-03-03 艾吉因生物股份有限公司 用於改善認知功能的方法和組合物
JP6804469B2 (ja) 2015-04-29 2020-12-23 ヤンセン ファーマシューティカ エヌ．ベー． ベンゾイミダゾロン及びベンゾチアゾロン化合物並びにａｍｐａ受容体調節因子としてのそれらの使用
CA2983826A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
CA2984305C (en) 2015-04-29 2021-12-28 Janssen Pharmaceutica Nv Indolone compounds and their use as ampa receptor modulators
CA2984307A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
HUE050083T2 (hu) 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok
EP3371170B1 (en) 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
CA2064815C (en) * 1990-06-07 1999-11-16 Alan Duncan Robertson Therapeutic heterocyclic compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
BR9106978A (pt) * 1990-10-15 1993-09-28 Pfizer Derivados de indol
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
CA2340999C (en) 2005-01-04
NO951633D0 (no) 1995-04-28
US5886008A (en) 1999-03-23
NO309652B1 (no) 2001-03-05
EP0666858A1 (en) 1995-08-16
GR3036579T3 (en) 2001-12-31
DE69330351D1 (de) 2001-07-19
FI934825A0 (fi) 1993-11-01
WO1994010171A1 (en) 1994-05-11
FI934825L (fi) 1994-05-03
DE69330351T2 (de) 2001-09-20
FI20002505A7 (fi) 2000-11-15
EP0666858B1 (en) 2001-06-13
BR9307348A (pt) 1999-05-11
PL308669A1 (en) 1995-08-21
ES2157224T3 (es) 2001-08-16
AU5329494A (en) 1994-05-24
ATE202102T1 (de) 2001-06-15
MY109696A (en) 1997-04-30
RU95109927A (ru) 1997-01-10
DK0666858T3 (da) 2001-08-27
PL176091B1 (pl) 1999-04-30
CA2148380C (en) 2001-08-14
CA2340999A1 (en) 1994-05-11
NO951633L (no) 1995-04-28
CZ110895A3 (en) 1995-11-15
PT666858E (pt) 2001-09-28
KR950704313A (ko) 1995-11-17
IL107386A0 (en) 1994-01-25
HUT66011A (en) 1994-08-29
AU685066B2 (en) 1998-01-15
CZ283001B6 (cs) 1997-12-17
ZA938137B (en) 1995-05-02
TW251284B (OSRAM) 1995-07-11
KR0163371B1 (ko) 1998-12-01
RU2134266C1 (ru) 1999-08-10
NZ257059A (en) 1997-07-27
CN1094727A (zh) 1994-11-09
JP2788551B2 (ja) 1998-08-20
EG20396A (en) 1999-02-28
IL107386A (en) 1999-03-12
JPH07508759A (ja) 1995-09-28
CN1051313C (zh) 2000-04-12
FI20002505L (fi) 2000-11-15
CA2148380A1 (en) 1994-05-11
HU222235B1 (hu) 2003-05-28
EP1094064A1 (en) 2001-04-25

Similar Documents

Publication Publication Date Title
FI111257B (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-aryyli-indolijohdannaisten valmistamiseksi sekä uudet välituoteyhdisteet
AU671959B2 (en) Indole derivatives
CN107406426B (zh) 作为rock抑制剂的环状脲类
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
CZ59996A3 (en) 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
FI92067B (fi) Menetelmä valmistaa terapeuttisesti aktiivisia mono- tai disubstituoituja (imidatsol-4-yyli)metyylipyrido/4,3-b/indol- ja atsepino/4,3-b/indol-1-oneja
AU2003279230A1 (en) AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
JP2004501918A (ja) Ｘａ因子阻害剤としての１−（ヘテロアリール−フェニル）−縮合ピラゾール誘導体
CA2645731A1 (en) N-substituted-azacyclylamines as histamine-3 antagonists
AU646679B2 (en) Novel 3-arylindole and 3-arylindazole derivatives
AU744540B2 (en) 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both
US20040167158A1 (en) Heterocyclic compounds for the treatment of migraine
PL172388B1 (pl) Pochodne indolu PL PL PL PL PL PL PL PL PL
JP2019519582A (ja) ベンゾジオキサン誘導体およびその医薬用途
CZ290416B6 (cs) Farmaceutický prostředek na bázi derivátu indolu
CA2685318A1 (en) 5-(aminoazacyclyl)-3-sulfonyl-1h-indazoles as 5-hydroxytryptamine-6 ligands for the treatment of cns disorders
SK144095A3 (sk) : Piperidinyltioindolové deriváty, spôsob ich prípravy a farmaceutické prostriedky obsahujúce tieto deriváty

Legal Events

Date Code Title Description
FD Application lapsed
MA Patent expired